[HTML][HTML] Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: current status in clinical trials
Y Song, Z Bi, Y Liu, F Qin, Y Wei, X Wei - Genes & diseases, 2023 - Elsevier
Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …
MAPK pathway inhibitors in thyroid cancer: preclinical and clinical data
L Schubert, ML Mariko, J Clerc, O Huillard, L Groussin - Cancers, 2023 - mdpi.com
Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation and survival. Overexpression and overactivation of members …
cell proliferation, differentiation and survival. Overexpression and overactivation of members …
Epigenetic modification and BRAF gene mutation in thyroid carcinoma
G Huang, J Chen, J Zhou, S Xiao, W Zeng, J Xia… - Cancer cell …, 2021 - Springer
Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively
increasing incidence rate has been observed in recent years, with 95% of thyroid cancer …
increasing incidence rate has been observed in recent years, with 95% of thyroid cancer …
Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal
Y Lu, Y Zhao, P Liu, X Xu - Endocrine-Related Cancer, 2023 - erc.bioscientifica.com
B-Raf kinase inhibitors such as vemurafenib (PLX4032) and dabrafenib have limited
therapeutic efficacy on BRAF-mutated thyroid cancer. Cancer stem cells (CSCs) play …
therapeutic efficacy on BRAF-mutated thyroid cancer. Cancer stem cells (CSCs) play …
Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens
Synthetic lethality offers a promising approach for developing effective therapeutic
interventions in cancer when direct targeting of driver genes is impractical. In this study, we …
interventions in cancer when direct targeting of driver genes is impractical. In this study, we …
Fibronectin contributes to a BRAF Inhibitor–driven invasive phenotype in thyroid cancer through EGR1, which can Be blocked by inhibition of ERK1/2
HM Hicks, N Pozdeyev, SB Sams, U Pugazhenthi… - Molecular Cancer …, 2023 - AACR
Mutations in BRAF are common in advanced papillary and anaplastic thyroid cancer (PTC
and ATC). However, patients with BRAF-mutant PTC currently lack therapies targeting this …
and ATC). However, patients with BRAF-mutant PTC currently lack therapies targeting this …
miR‐506‐loaded gelatin nanospheres target PENK and inactivate the ERK/Fos signaling pathway to suppress triple‐negative breast cancer aggressiveness
XL Liu, WJ Liu, Q Chen, J Liu, CQ Yang… - Molecular …, 2021 - Wiley Online Library
Triple‐negative breast cancer (TNBC) is the most malignant subtype of breast cancer. Some
microRNAs (miRNAs) were abnormally expressed in TNBC, and they are closely related to …
microRNAs (miRNAs) were abnormally expressed in TNBC, and they are closely related to …
Downregulation of cellular retinoic acid binding protein 1 fosters epithelial–mesenchymal transition in thyroid cancer
YC Hsu, WC Huang, CY Kuo, YS Li… - Molecular …, 2023 - Wiley Online Library
Cellular retinoic acid binding protein 1 (CRABP1) participates in the regulation of retinoid
signaling. Previous studies showed conflicting results regarding the role of CRABP1 in …
signaling. Previous studies showed conflicting results regarding the role of CRABP1 in …
Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies
A De Carli, Y Kapelyukh, J Kursawe… - npj Systems Biology …, 2024 - nature.com
In vertical inhibition treatment strategies, multiple components of an intracellular pathway
are simultaneously inhibited. Vertical inhibition of the BRAFV600E–MEK-ERK signalling …
are simultaneously inhibited. Vertical inhibition of the BRAFV600E–MEK-ERK signalling …
[HTML][HTML] The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells
Y Chen, Y Sang, S Li, J Xue, M Chen, S Hong… - Translational …, 2024 - Elsevier
BRAF or RAS mutation-induced aberrant activation of the mitogen-activated protein kinase
(MAPK) pathway is frequently observed in human cancers. As the key downstream node of …
(MAPK) pathway is frequently observed in human cancers. As the key downstream node of …